25-03-2023, 10:00 AM
Chapter 1.
Joan Kolar, Ph.D., head chemist for GynaDyne, a small pharmaceutical company specializing in women's products, sat in her small but adequate office. To the right of her desk were two floor to ceiling glass windows, looking out onto the experimental laboratory that was her domain. The windows were fitted with blinds that could be closed for privacy if needed. Mostly Joan kept them open, like they were now. It was six in the evening on a Friday and an hour past normal quitting time. Two of the associate chemists were finishing up their work for the day and for the week. The others had already left.
Joan was contemplating doing something that, as a chemist working on new formulas wasn't all that rare, but not encouraged by GynaDyne's front office.
Both of the associate chemists finished up what they were doing at almost the same time. Her office door was open and, as they left the lab they turned, waved and called out in unison, "Good night Joan." Joan smiled and waved back.
Another head chemist with a Ph.D. might have made them call her Dr. Kolar, but Joan was very laid back and informal, except when it came to the work at hand. "Our jobs are to be as careful and precise as we can." She didn't brook sloppy work. Any hand written notes had to be meticulously taken and then just as meticulously transcribed into the computer.
Joan got up and went to the door leading from the lab to the hallway. She locked the door then turned out the lights in the lab. Her office was still brightly lit though. She made her way through the lab to her office and to the small safe behind her desk. Only she and the CEO of the company had the combination to it. Among other proprietary drug formulas she kept there, as well as samples of same, was a small vile of the new drug Aphrodite.
Aphrodite had been specifically engineered to stimulate not only the general sexual arousal sites of the human brain, but also those sites specific to female arousal
Joan sat down at her desk and contemplated the little dark brown vial in her hand.
She took in a deep breath, held if for a couple of seconds, then let it out slowly. She did it again.
"Okay," she told herself out loud, "I'm going to do it."
The "it" that she was going to do was to dose herself with Aphrodite to be the first to see if and how well it worked.
The associate chemists she worked with had called it Viagra for women, but it was much more than that. Viagra worked, more or less, mechanically. It increased the production of nitric oxide in a man's blood and nitric oxide relaxes the arteries allowing more and easier blood flow. It also inhibited an enzyme that degraded this process. It also worked from the brain stem, through the spinal column, to the genitals. This allowed more blood flow into the penis when a man is contemplating having sex or involved in a sexual situation and, voila, he will get a fuller and more complete erection. Unless, of course, he has a damaged or blocked artery feeding the penis, then Viagra doesn't help him.
Aphrodite worked through various chemicals on different parts of a woman's brain to enhance sexual arousal, sexual desire, and pleasurable emotions. Of course, it also affected the various nerves that lead to and from the pelvic area and the genitals giving a woman more sensitivity there. In her research Joan had discovered that during sexual arousal there is an area of the cortex of women associated with pain that is activated, showing a distinct connection between pain and pleasure.
Two of the many effects of the aphrodisiac that she had created was a temporary increase of testosterone, normally associated with men, but necessary for women also for sexual desire. But the other effect was that the testosterone initiated the release of dopamine, the feel good hormone, which make us want to feel that pleasure again.
A third effect of Aphrodite was that it stimulated a woman's body to create the pheromone copulance, normally only produced by ovulating women. Copulance, researchers had found, even in amounts undetectable by a man, increased his own testosterone levels and, therefore, his desire for sex.
Joan was familiar with the literature of all the chemicals that went into Aphrodite, as well as being personally familiar with most of them from prior work and experimentation. That is, she knew down to the micro-dose how they should work and knew that they were not dangerous in the sense that they would give her a heart attack, stroke, convulsions, psychosis, or any other serious problems. They were all chemicals that had been used safely in other human applications, but not altogether at once.
GynaDyne had just gotten permission from the FDA to start human trials on Aphrodite and Joan was in charge of the process of setting up trial protocols. So what Joan was about to do wasn't in any sense illegal but, as the head chemist, it was frowned upon for her to be the first guinea pig.
Joan shrugged and smiled. Oh well, she told herself, it's unlikely if the Board of Directors finds out what I've done that they'll fire me. Five years ago Joan had come up with the vaginal gel formulation that also works to give a woman the pleasant feeling of sexual readiness and that was GynaDyne's biggest money-maker now, raking in a few hundred million dollars a year.
Joan had already decided to take the vial home with her for the weekend. If her first dosing didn't work the way she hoped it would then she could adjust it and try it again at home.
Joan Kolar, Ph.D., head chemist for GynaDyne, a small pharmaceutical company specializing in women's products, sat in her small but adequate office. To the right of her desk were two floor to ceiling glass windows, looking out onto the experimental laboratory that was her domain. The windows were fitted with blinds that could be closed for privacy if needed. Mostly Joan kept them open, like they were now. It was six in the evening on a Friday and an hour past normal quitting time. Two of the associate chemists were finishing up their work for the day and for the week. The others had already left.
Joan was contemplating doing something that, as a chemist working on new formulas wasn't all that rare, but not encouraged by GynaDyne's front office.
Both of the associate chemists finished up what they were doing at almost the same time. Her office door was open and, as they left the lab they turned, waved and called out in unison, "Good night Joan." Joan smiled and waved back.
Another head chemist with a Ph.D. might have made them call her Dr. Kolar, but Joan was very laid back and informal, except when it came to the work at hand. "Our jobs are to be as careful and precise as we can." She didn't brook sloppy work. Any hand written notes had to be meticulously taken and then just as meticulously transcribed into the computer.
Joan got up and went to the door leading from the lab to the hallway. She locked the door then turned out the lights in the lab. Her office was still brightly lit though. She made her way through the lab to her office and to the small safe behind her desk. Only she and the CEO of the company had the combination to it. Among other proprietary drug formulas she kept there, as well as samples of same, was a small vile of the new drug Aphrodite.
Aphrodite had been specifically engineered to stimulate not only the general sexual arousal sites of the human brain, but also those sites specific to female arousal
Joan sat down at her desk and contemplated the little dark brown vial in her hand.
She took in a deep breath, held if for a couple of seconds, then let it out slowly. She did it again.
"Okay," she told herself out loud, "I'm going to do it."
The "it" that she was going to do was to dose herself with Aphrodite to be the first to see if and how well it worked.
The associate chemists she worked with had called it Viagra for women, but it was much more than that. Viagra worked, more or less, mechanically. It increased the production of nitric oxide in a man's blood and nitric oxide relaxes the arteries allowing more and easier blood flow. It also inhibited an enzyme that degraded this process. It also worked from the brain stem, through the spinal column, to the genitals. This allowed more blood flow into the penis when a man is contemplating having sex or involved in a sexual situation and, voila, he will get a fuller and more complete erection. Unless, of course, he has a damaged or blocked artery feeding the penis, then Viagra doesn't help him.
Aphrodite worked through various chemicals on different parts of a woman's brain to enhance sexual arousal, sexual desire, and pleasurable emotions. Of course, it also affected the various nerves that lead to and from the pelvic area and the genitals giving a woman more sensitivity there. In her research Joan had discovered that during sexual arousal there is an area of the cortex of women associated with pain that is activated, showing a distinct connection between pain and pleasure.
Two of the many effects of the aphrodisiac that she had created was a temporary increase of testosterone, normally associated with men, but necessary for women also for sexual desire. But the other effect was that the testosterone initiated the release of dopamine, the feel good hormone, which make us want to feel that pleasure again.
A third effect of Aphrodite was that it stimulated a woman's body to create the pheromone copulance, normally only produced by ovulating women. Copulance, researchers had found, even in amounts undetectable by a man, increased his own testosterone levels and, therefore, his desire for sex.
Joan was familiar with the literature of all the chemicals that went into Aphrodite, as well as being personally familiar with most of them from prior work and experimentation. That is, she knew down to the micro-dose how they should work and knew that they were not dangerous in the sense that they would give her a heart attack, stroke, convulsions, psychosis, or any other serious problems. They were all chemicals that had been used safely in other human applications, but not altogether at once.
GynaDyne had just gotten permission from the FDA to start human trials on Aphrodite and Joan was in charge of the process of setting up trial protocols. So what Joan was about to do wasn't in any sense illegal but, as the head chemist, it was frowned upon for her to be the first guinea pig.
Joan shrugged and smiled. Oh well, she told herself, it's unlikely if the Board of Directors finds out what I've done that they'll fire me. Five years ago Joan had come up with the vaginal gel formulation that also works to give a woman the pleasant feeling of sexual readiness and that was GynaDyne's biggest money-maker now, raking in a few hundred million dollars a year.
Joan had already decided to take the vial home with her for the weekend. If her first dosing didn't work the way she hoped it would then she could adjust it and try it again at home.
![[+]](https://xossipy.com/themes/sharepoint/collapse_collapsed.png)